Hexaxim vaccine passes safety review in korean infants
NCT ID NCT06793826
First seen Feb 24, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study looked at the safety of the Hexaxim vaccine, which protects against diseases like hepatitis B and Haemophilus influenzae type b, in infants starting at 2 months old in South Korea. Over 700 babies received the vaccine as part of routine care, and researchers tracked any side effects or reactions. The goal was to make sure the vaccine is safe for everyday use in this age group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 001
Seoul, South Korea
-
Investigational Site Number : 002
Cheonan, South Korea
Conditions
Explore the condition pages connected to this study.